다케다약품공업 ADR (TAK)

개요 뉴스 가격 이력 옵션 체인 토론 예측 배당 이력

Relative Volume:

다케다약품공업 ADR Stock (TAK) Company Profile

Takeda Pharmaceutical Co Adr

Healthcare (1195)

@takedapharma

최신 SEC 제출 서류

TAK's Discussions on Twitter

TAK을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
TAK	13.27	42.13B	30.27B	1.93B	3.45B	0.444
ZTS	176.28	78.47B	9.15B	2.43B	2.31B	4.92
HLN	9.545	42.84B	14.26B	1.55B	0	0.3327
TEVA	17.04	19.19B	16.77B	-959.00M	1.37B	-2.00
VTRS	13.22	15.67B	15.24B	-646.50M	1.88B	1.53

다케다약품공업 ADR Stock (TAK) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2023-03-16	업그레이드	BofA Securities	Neutral → Buy
2022-07-19	업그레이드	Cowen	Market Perform → Outperform
2021-10-07	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2021-04-19	다운그레이드	JP Morgan	Overweight → Neutral
2019-11-01	개시	Cowen	Market Perform
2019-08-15	다운그레이드	Daiwa Securities	Outperform → Neutral

다케다약품공업 ADR 주식(TAK)의 최신 뉴스

다케다약품공업 ADR (TAK) 재무 분석

다케다약품공업 ADR (TAK)

다케다약품공업 ADR Stock (TAK) Company Profile

TAK을(를) 다른 주식과 비교

다케다약품공업 ADR Stock (TAK) Upgrades & Downgrades

다케다약품공업 ADR 주식(TAK)의 최신 뉴스

Weekly Upgrades and Downgrades - InvestorPlace

Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform - Quantisnow

Protein Therapeutics Market Size to be Worth USD 549.4 billion by 2031, at a CAGR of 6.3% | Transparency Market Research, Inc. - GlobeNewswire Inc.

T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.

Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading - MSN

Earnings call: Takeda reports robust H1 growth, revises full-year guidance - Investing.com Australia

Earnings call: Takeda reports robust H1 growth, revises full-year guidance By Investing.com - Investing.com South Africa

Torm Plc (NASDAQ: TRMD): Getting A Free Pass? - Stocks Register

What Analysts Were Expecting After Checkpoint Therapeutics Inc (NASDAQ: CKPT) rose 2.03% - Stocks Register

Spain Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research

Thailand Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research

Dyne Therapeutics Inc (DYN) gets rating Reiterated from Chardan Capital Markets - Knox Daily

W & T Offshore Inc (WTI) receives a Buy rating from Stifel - Knox Daily

JP Morgan Upgrades Mister Car Wash Inc (MCW) to an Overweight from a Neutral - Knox Daily

BofA Securities upgrades Takeda Pharmaceutical Co ADR (TAK) rating to a Buy - Knox Daily

What Did We Find About Insider Trading At Ovintiv Inc (NYSE: OVV)? - Stocks Register

Mizuho analysts downgrades a Neutral rating for Squarespace Inc (SQSP) - Knox Daily

Barclays gives an Equal weight recommendation for Kilroy Realty Corp. (KRC) - Knox Daily

Microchip Technology, Inc. (MCHP) receives a Hold rating from Truist - Knox Daily

Cantor Fitzgerald’s latest rating for EBAY stock - Knox Daily

Watch this stock’s price performance: Takeda Pharmaceutical Co ADR (NYSE:TAK) - US Post News

North America Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research

Mexico Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research

China Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research

Italy Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research

Checking in on Takeda Pharmaceutical Co ADR (TAK) after recent insiders movement - Knox Daily

AHH stock rated a Buy by Stifel - Knox Daily

IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, - openPR

IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, Pipeline, Medication, Therapies, Treatment Market and Companies by DelveInsight - Barchart

Ratios in Focus: Analyzing Takeda Pharmaceutical Co ADR (TAK)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Taking a look at what insiders are doing to gauge the Takeda Pharmaceutical Co ADR (TAK)’s direction - Knox Daily

Brookline Bancorp, Inc. [BRKL] Records 50-Day SMA of $10.01 - Knox Daily

Crescent Energy Co. [CRGY] Records 200-Day SMA of $11.56 - Knox Daily

Tetra Tech, Inc. [TTEK] EVP, CFO makes an insider purchase of 36,830 shares worth 1.72 million. - Knox Daily

TAK’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle

Vatroslav Mateljic Appointed General Manager of Takeda Canada - Quantisnow

Ipsen provides update on CONTACT-02 Phase III trial in - GlobeNewswire

Biotech Soars, And Then Dives, On $5 Billion Opportunity - Investor's Business Daily

France Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research

다케다약품공업 ADR (TAK) 재무 분석

매출

순이익

현금흐름

주당 순 이익

TAK과 유사한 종목